Form 4: Marimed CEO Jon Levine Executes Stock Transactions

Marimed's CEO, Jon Levine, reports stock transactions including RSU conversions and sales to cover tax obligations.

Summary

• On April 27, 2024, Jon Levine, the President and CEO of Marimed Inc., converted 138,889 Restricted Stock Units (RSUs) into common stock.
• On April 29, 2024, Levine sold 50,031 shares of common stock at a price of $0.2553 per share.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 10, 2023, to cover tax withholding obligations related to the vesting of RSUs.
• Following these transactions, Levine directly owns 20,317,878 shares of common stock and indirectly owns 6,684,640 shares through the Jon Levine Family Trust.
• The RSUs vest in equal installments every six months following the grant date of October 27, 2022.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock transactions by an executive, which is a normal occurrence. The sale was pre-planned to cover tax obligations.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Insider transactions are a normal part of corporate governance and are regularly disclosed by executives at publicly traded companies.
• The use of Rule 10b5-1 trading plans is a common practice to avoid accusations of insider trading, allowing executives to sell shares at predetermined times and prices.
• Comparable companies such as Curaleaf, Trulieve, and Green Thumb Industries also have executives who regularly report stock transactions.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares in the market.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates